UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2017

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-37348** (Commission File Number) 46-4348039 (IRS Employer Identification No.)

100 River Ridge Drive, Norwood, MA (Address of principal executive offices)

02062 (Zip Code)

Registrant's telephone number, including area code: (617) 963-0100

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Item 7.01. Regulation FD Disclosure.

On November 9, 2017, Corbus Pharmaceuticals Holdings, Inc. (the "Company") used the slides attached hereto as Exhibit 99.1 in connection with management presentations to describe its business.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.	Description
99.1	Investor Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Dated: November 9, 2017

By: <u>/s/ Yuval Cohen</u> Name: Yuval Cohen Title: Chief Executive Officer

EXHIBIT INDEX

 Exhibit No.
 Description

 99.1
 Investor Presentation.



Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases

NASDAQ:CRBP www.corbuspharma.com



This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CORBI






Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases

	Indication	Patient Population	Phase of Development	Orphan Designation	Fast Track Status	Open-Label Extension	Nondilutive Funding	Next Catalyst
Autoimmune	Systemic Sclerosis (SSc)	90,000 (US+EU)	Launch Phase 3	\checkmark	~	1	State of the second	Plan to commence Phase 3 study Q4 2017
	Dermatomyositis (DM)	70,000 (US)	Positive Phase 2			1	√ NIH Funded ¹	Positive Topline Phase 2 data reported Q4 2017
	Systemic Lupus Erythematosus (SLE)	500,000 (US+EU)	Launch Phase 2			11117	V NIH Funded ¹	Plan to commence Phase 2 study Q4 2017
Genetic / Inflammatory	Cystic Fibrosis (CF)	75,000 (worldwide)	Launch Phase 2b	√	~	A	CF Foundation ²	Plan to commence Phase 2b study by EoY 2017

CORBUS


NIH grants fund Phase 2 trials of anabasum in dermatomyositis and systemic lupus erythematosus; Corbus retains all rights to the product and owns the IND data
 Awarded 2015; project completed

Normal Inflammatory Process vs. Chronic Inflammation






Resolution of Chronic Inflammation and Fibrosis




Endocannabinoids Play a Unique Role in Inflammation and Fibrosis MOA of CB2 agonism: triggers resolution of inflammation¹ Resolution of Inflammation and Fibrosis CB2 Endocannabinoid System

7 1: Shinohara 2012

The Endocannabinoid System Has a Dual Role




Attractive Candidate for Rare + Chronic Inflammatory / Fibrotic Diseases




Diffuse Cutaneous Systemic Sclerosis:

- Positive Phase 2 data
- Ongoing open-label extension
 Significant and clinically meaningf
 - Significant and clinically meaningful results demonstrated at 28-weeks
- Phase 3 study planned for Q4 2017
- Potential approval in 2020









- Anabasum was well tolerated
- No serious or severe anabasum-related TEAEs noted
- · Most common adverse events were mild/moderate:
 - Dizziness (22% in anabasum-treated subjects vs. 13% in placebo-treated subjects)
 - Fatigue (19% in anabasum-treated subjects vs. 7% in placebo-treated subjects)






Primary Endpoint in Planned Phase 3 Study

Improved Patient Reported Skin Symptoms



Y


Additional Efficacy Outcomes Favor Anabasum



16 1: P-values are based on LS mean difference, one-sided p-values shown if P ≤ 0.10 (pre-specified)


CORBUS

Improvements in ACR-CRISS Scores




On Target Effect: Anabasum Reduces <u>Inflammation</u> in Skin (Histology Analysis)

18



Change in *inflammation* after only 12 weeks of treatment

On Target Effect: Anabasum Reduces <u>Fibrosis</u> in Skin (Histology Analysis)



Ongoing Open-Label Extension - Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks




- Achieved reduction in mRSS of 8.4 points from start of study exceeding clinically important improvement
- · 75% of subjects achieved degree of improvement in mRSS correlated with improved survival
- Clinical benefit supported by improvement in multiple secondary outcomes and a continued favorable safety profile
- No severe or serious adverse events (AEs) and no clinically significant laboratory abnormalities related to the drug

CORBU


 Results were presented at the 2017 American College of Rheumatology ("ACR") Annual Meeting




Demonstrated Significant Improvement in mRSS in Open-Label Extension – Primary Outcome for Upcoming Phase 3



ACR CRISS reached 71% (median) from start of study with 44% of subjects achieving a score > 70%



Planned Design of Upcoming Phase 3 Study





Cystic Fibrosis

CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. CF is characterized by chronic lung inflammation that leads to lung damage and fibrosis.

ŤŤ4



75,000 Patients worldwide



40 Years

Average life expectancy of CF patients

Key Takeaways



Life-threatening, rare disease



Inflammation and fibrosis play key role in CF morbidity and mortality




Need for safe and effective drugs that target chronic inflammation and fibrosis is unmet and recognized




Pharmacoeconomics are proven and favorable






Design of Completed Phase 2 Study




- Anabasum was well tolerated
- No serious or severe anabasum-related TEAEs noted
- Most common anabasum-related mild adverse event:
 - Dry mouth (mild, 13% vs 0% in placebo)
- · FEV-1 remained stable throughout the study across all cohorts

CORBUS


Anabasum Increases Time to First New Pulmonary Exacerbations Treated with Oral or IV Antibiotics



Consistent Reduction in Key Inflammatory Biomarkers (Sputum)



Reduction with anabasum 20 mg BID compared to placebo (Log₁₀)



Dermatomyositis

Chronic systemic autoimmune disease characterized by inflammation of skin and muscles

70,000 Patients in the U.S. + EU

Skin & Muscle

Involvement can cause significant morbidity and mortality from interstitial lung disease

No FDA

Approved therapies for overall disease activity



Key Takeaways



Treated with immunosuppressive therapies, but with significant toxicities




Single center study underway at University of Pennsylvania



Collaborating with NIH

CORBUS

Dermatomyositis Phase 2 Clinical Study




Safety and Tolerability Summary

- Anabasum was well tolerated and demonstrated a favorable safety profile
- No evidence of immunosuppression
- · No serious or severe side effects related to anabasum
- · No subjects dropped out of the study

CDASI was developed to measure multiple inflammatory elements in the skin¹




CDASI Score – Anabasum Demonstrated Clinically Meaningful Improvement



Anabasum improved CDASI by 9.3 vs. 3.7 for placebo; p = 0.04, 2-sided MMRM

36

Additional Efficacy Outcomes Favor Anabasum





Strong Evidence of Clinical Benefit Merits Further Development in Dermatomyositis

- First potential treatment for skin-predominant dermatomyositis to show clinical benefit in a double-blind, randomized, placebo-controlled trial
- Will meet with regulatory authorities to review data and determine next steps in clinical development plan

CORBUS





Management Team



Yuval Cohen, PhD Chief Executive Officer, Director

Co-founder and former President of Celsus Therapeutics (CLTX). Expertise in developing anti-inflammatory drugs including for CF



Sean Moran, CPA, MBA Chief Financial Officer

Former CFO: InVivo (NVIV), Celsion (CLSN), Transport Pharma, Echo Therapeutics (ECTE) & Anika Therapeutics (ANIK)



Mark Tepper, PhD President & Chief Scientific Officer

Former VP U.S. Research & Operations, EMD Serono; Sr. Investigator, Bristol-Myers Squibb



Barbara White, MD Chief Medical Officer

Board-certified Rheumatologist and clinical immunologist. Previously SVP and Head, R&D Stiefel, a GSK company, VP and Head of Immunology Therapeutic Area for UCB, VP and Senior Director of Clinical Development for MedImmune, and Director of Medical Affairs, Inflammation Therapeutic Area for Amgen



Board of Directors



Amb. Alan Holmer Ret.- Chairman of the Board

- Former CEO of PhRMA (1996-2005)
- Over two decades of public service in Washington, D.C. including Special Envoy to China (2007-2009)
- Former board member of Inspire Pharma
- Chairman of the Board of the Metropolitan Washington, D.C. Chapter of the Cystic Fibrosis Foundation



Avery W. (Chip) Catlin

- CFO Celldex Therapeutics (CLDX) since 2000
- Over 20 years experience in industry: Repligen (CFO) and Endogen (CFO)





Renu Gupta, MD

- Over 25 years of R&D, regulatory and senior management experience in the biopharma industry
- Former EVP, and CMO of Insmed, a specialty CF company
 - Former VP and Head of U.S. Clinical Research and Development, Novartis
- Senior Advisor to CEOs and Boards of biopharma

Paris Panayiotopoulos

- Former President and Chief Executive Officer and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc., which was acquired by Takeda Pharmaceuticals for \$5.2 billion
- Former President of EMD Serono, Inc., President of the Serono Research and Development Institute and President of Merck Serono, Tokyo, Japan
- Has led multiple partnerships, including those with Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd. and Incyte Corporation



40


David Hochman

- Managing Partner of Orchestra Medical Ventures
- Over 19 years of venture capital and investment banking experience
- Former Managing Director of Spencer Trask Ventures, Inc.



Scientific Advisory and Principal Investigators

Scientific Advisors		Principal Investigators	
Michael Knowles, MD	THE UNIVERSITY of NORTH CAROLINA at CHAPEL HILL	Robert Spiera, MD US PI – SSc	HOSPITAL FOR SPECIAL SURGERY
Charles Serhan, PhD	HARVARD MEDICAL SCHOOL	Christopher Denton, PhD, FRCI EU PI – SSc	Royal Free London
		James Chmiel, MD US PI – CF	CASE WESTERN RESERVE
		Stuart Elborn, MD, FRCP EU PI – CF	toyal Brompton & Harefield
		Victoria Werth, MD US PI – DM	Penn
		Meggan Mackay, MD US PI – SLE	HOFSTRA NORTHWELL SCHOOL of MEDICINE AT HOFSTRA UNIVERSITY
41			




Financial Profile: CRBP (NASDAQ)



CORBUS

* Based on November 7, 2017 closing price of \$6.85 per share ** As of November 7, 2017





Corbus Pharmaceuticals Holdings, Inc.

617.963.0100 info@corbuspharma.com www.corbuspharma.com

100 River Ridge Drive Norwood, MA 02062

